|
Commitments and Contingencies (Details Textual) (USD $)
|
1 Months Ended | 9 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2012
|
Sep. 30, 2012
UFRF [Member]
|
Sep. 30, 2012
Intrexon [Member]
|
Sep. 30, 2012
Intrexon [Member]
Filing of First Investigational New Drug Application [Member]
|
Sep. 30, 2012
Intrexon [Member]
Filing of First New Drug Application [Member]
|
Sep. 30, 2012
Intrexon [Member]
First Regulatory Approval of Oragenics Product [Member]
|
Sep. 30, 2012
Intrexon [Member]
Clinical study Phase 2 [Member]
|
Sep. 30, 2012
Intrexon [Member]
Clinical study Phase 3 [Member]
|
Sep. 30, 2012
MU1140 [Member]
|
Sep. 30, 2012
Smart Replacement Therapy [Member]
|
|
| Commitments and Contingencies (Textual) [Abstract] | ||||||||||
| License agreement Date | Jun. 22, 2000 | Aug. 04, 1998 | ||||||||
| License Agreement Date First Amended | Sep. 15, 2000 | Sep. 15, 2000 | ||||||||
| License Agreement Date Second Amended | Jul. 10, 2002 | Jul. 10, 2002 | ||||||||
| License Agreement Date Third Amended | Sep. 25, 2002 | Sep. 25, 2002 | ||||||||
| License Agreement Date Fourth Amended | Mar. 17, 2003 | Mar. 17, 2003 | ||||||||
| Patent effective date | Mar. 04, 1997 | |||||||||
| Patent Right Expire Date | Jun. 07, 2015 | |||||||||
| Common stock issued | 6,285,619 | 599,940 | 4,392,425 | |||||||
| Company obligation to pay from percentage of selling price of product | 5.00% | |||||||||
| Company obligation to pay from all revenue receive from sublicenses | 20.00% | |||||||||
| License agreement amount | $ 50,000 | |||||||||
| Minimum Royalty payment to UFRF | 100,000 | |||||||||
| Royalty payment to UFRF in installment | 25,000 | |||||||||
| Company obligated to spend on research and development, regulatory | $ 1,000,000 | |||||||||
| Company will pay on Quarterly basis out of gross profit | 25.00% | |||||||||
| Company obligation to pay from all revenue receive from sublicenses | 50.00% | |||||||||
| Channel Agreement | 18 months | |||||||||
| Termination Notice Period | 90 days | |||||||||
| Percentage of number of shares of common stock equal to Base Shares | 1.00% | 2.50% | 3.00% | 1.50% | 2.00% | |||||
| Maximum percentage of primary investment securities to investment of shares issued | 10.00% | |||||||||